Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis
2003; Karger Publishers; Volume: 206; Issue: 2 Linguagem: Inglês
10.1159/000068451
ISSN1421-9832
AutoresRICHARD A. KRATHEN, Staci Ward, Madeleine Duvic,
Tópico(s)Fungal Infections and Studies
Resumo<i>Background:</i> Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin<sup>®</sup>) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma. <i>Objective:</i> To determine whether bexarotene is effective in treating LyP. <i>Methods:</i> Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene. <i>Results:</i> A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients. <i>Conclusions:</i> Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.
Referência(s)